NCT06993480View on ClinicalTrials.gov

A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 18, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 1, 2026

Conditions
Chronic Hepatitis B
Interventions
DRUG

AHB-137

AHB-137 300 mg will be injected subcutaneously once a week (total 24 weeks).

Trial Locations (1)

Unknown

RECRUITING

The Second Affiliated Hospital of Chongqing Medical University, Chongqing

All Listed Sponsors
lead

Ausper Biopharma Co., Ltd.

INDUSTRY

NCT06993480 - A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB) | Biotech Hunter | Biotech Hunter